CancerIQ
CancerIQ is a Chicago-based precision health intelligence platform that helps U.S. health systems scale genomics-based cancer risk assessment, hereditary screening, and high-risk care management through EHR-integrated clinical decision support, automated documentation, and a multi-lab genetic-testing marketplace.
- Company typePrivate
- Founded2013
- HeadquartersChicago, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What CancerIQ does
CancerIQ is a cloud-based precision health intelligence platform founded in 2013 and headquartered in Chicago, Illinois (Delaware-incorporated). It is purpose-built for healthcare providers — health-system oncology and genetics programs, dedicated breast centers, primary-care networks, and EHR/health-IT stakeholders — and is implemented at more than 200 clinical locations across more than 60 U.S. health systems. The platform combines evidence-based risk models (Tyrer-Cuzick, NCCN guidelines) with clinical decision support, automated pedigree and documentation generation, longitudinal care-plan management with patient/provider alerts, and analytics/revenue-tracking dashboards (including Commission on Cancer Standard 4.4 reporting). It is exposed through four role-based portals (Navigator, Specialist, Manager & Registry, Analytics) and a REST API gateway (api.canceriq.com) with Auth0-based SSO, and is bidirectionally integrated with Epic (App Orchard) and Cerner App Gallery.
CancerIQ monetizes primarily through annual, quote-based enterprise SaaS subscriptions sold via a sales-led, demo-driven motion ("Book a Demo" CTA) to enterprise buyers, with implementation and customer-success services layered on top of each contract. Two adjacent revenue streams are professional services/customer success (workflow observation, EHR integration design, program optimization) and a virtual-care service (CIQ Complete) that connects patients to a telehealth genetic-counseling network. Distribution is reinforced through the CancerIQ Lab Network — a marketplace of anchor genetic-testing labs (Invitae, Myriad, Eurofins EGL, Eurofins NTD, LabCorp) — and through EHR app-store presence. CancerIQ has raised a $14 million Series B (March 2022, co-led by Merck GHI and Amgen Ventures) plus a 2024 growth package from Decathlon Capital Partners, and has grown its screened-patient base to over 300,000.
CancerIQ firmographics
Firmographics- Name
- CancerIQ
- Legal name
- CancerIQ, Inc.
- Website
- https://canceriq.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CancerIQ is a Chicago-based precision health intelligence platform that helps U.S. health systems scale genomics-based cancer risk assessment, hereditary screening, and high-risk care management through EHR-integrated clinical decision support, automated documentation, and a multi-lab genetic-testing marketplace.
- Ownership category
- akta.pro rank
CancerIQ industry classification
Industry- Product category
- Precision Health / Hereditary Cancer Risk Software
- NAICS
- Software Publishers (51321), Computer Systems Design and Related Services (5415)
- SIC
- Services-Prepackaged Software (7372), Services-Health Services (8000), Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)
- akta.pro secondary industry
- Oncology Telemedicine Platforms (HLALAGAH)
Keywords
Where CancerIQ is headquartered
LocationHeadquarters
- HQ city
- Chicago
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
CancerIQ business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Enterprise SaaS Subscription (Software & Services): Recurring SaaS subscription contracts sold to enterprise healthcare buyers (health systems, breast centers, oncology and genetics programs, primary care). Pricing is quote-based and not publicly disclosed. Bundles core platform modules (Screening, Risk Assessment, Patient Navigation, Care Plan Management, Analytics & Revenue Tracking) plus professional services for workflow planning, EHR integration, and customer success support. Customers are referenced at 200+ clinical locations.
- Professional Services / Customer Success: Implementation and customer success services including initial workflow observation, customized implementation planning, EHR integration design, and ongoing program optimization, often delivered alongside the SaaS subscription to drive adoption and ROI.
- Virtual Care / Genetic Counseling Services: Virtual care offering (CIQ Complete Call) that connects patients to genetic counseling and telehealth services, generating downstream clinical services revenue tied to genetic risk assessment and counseling encounters.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise SaaS — quote-based |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels9 records
CancerIQ product offering
Product offeringCore offering
CancerIQ is a cloud-based precision health intelligence platform that health systems use to identify patients at hereditary cancer risk, run genetic risk assessments at the point of care, and navigate high-risk patients into appropriate genetic testing, screening and preventive care. The platform combines risk-stratification algorithms, automated pedigree and documentation generation, a multi-lab test ordering marketplace, EHR-native workflows, longitudinal care management and analytics. It is sold primarily as an enterprise SaaS subscription with professional services, and is deployed across 200+ clinical locations in the United States.
Product overview
CancerIQ is a platform-plus-modules architecture rather than a single monolithic product. The CancerIQ Platform serves as the core precision health intelligence solution, layered with four primary workflow modules — Navigator (patient screening), Specialist (genetic-counselor workspace), Manager (longitudinal patient management & registry), and Analytics (reporting, including CoC Standard 4.4 dashboards) — and is complemented by the services Customer Success and CIQ Complete (telehealth genetic counseling). On top of this core, CancerIQ offers use-case solutions: REACH (For Oncology), For Genetics, For Breast Programs (breast centers), and For EHRs (EHR integration). The platform is further extended by the CancerIQ Lab Network, a marketplace of trusted genetic testing labs (Invitae, Myriad Genetics, Eurofins EGL, Eurofins NTD, LabCorp) embedded directly in the ordering workflow. Modules and solutions are designed to be used together or with the EHR integration.
Differentiator
Problem solved
Functional benefit
Products and services
- CancerIQ Platform Integrated precision health intelligence SaaS platform that helps health systems scale access to genomics and innovations in oncology, covering screening, risk assessment, patient navigation, care plan management, and analytics & revenue tracking. Powered by what CancerIQ describes as healthcare's largest precision prevention dataset; deployed across 200+ clinical locations.
- CIQ Complete (Virtual Care) Virtual care service that connects patients to CancerIQ's telehealth genetic counseling network, providing expert genetic guidance remotely as a downstream services offering tied to genetic risk assessment encounters.
- CancerIQ Lab Network Marketplace module of trusted genetic testing labs (Invitae, Myriad Genetics, Eurofins EGL, Eurofins NTD, LabCorp) embedded in the CancerIQ platform that prepopulates test requisitions and insurance prior-authorization forms and enables ordering from any vendor at the point of care.
Companies that use CancerIQ
Customer profileNamed customers16 records
Segments4 records
Ideal customer profiles4 records
CancerIQ technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration9 records
AI capability7 records
Feature9 records
CancerIQ partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered flagship diagnostic partner, flagship clinical partner for lung cancer screening, flagship research partner, industry consortium membership, anchor member of canceriq lab network, flagship telehealth partner, flagship ehr integration partner, founding research partner, early strategic partner and minor industry reference.
- Rhythm Biosciencesflagship diagnostic partnerStrategic partnership integrating Rhythm's geneType Cancer Risk Assessment (polygenic risk scores combined with clinical/family history data across six cancer types, providing 5-year and lifetime risk estimates) into CancerIQ's workflow across 60+ health systems. Expands CancerIQ's diagnostic offerings while giving Rhythm broader commercial reach through U.S. healthcare providers.
- Azra AIflagship clinical partner for lung cancer screeningPartnership combining CancerIQ's risk-based patient identification and engagement with Azra AI's AI-powered imaging follow-up for low-dose CT lung cancer screening. Real-world Nebraska Medicine deployment showed a 270% monthly increase in scheduled LDCT scans and successful Stage 1A lung cancer diagnoses; Azra AI reports 98% precision, 7-day reduction in time to treatment, and 20% annual net patient revenue growth for partners.
- Fred Hutchinson Cancer Centerflagship research partnerCo-published a study in Genetics in Medicine (Feb 25, 2025) showing outstanding data integrity when transitioning from Progeny to CancerIQ. Research/clinical collaboration validating the platform's data quality.
- CancerX Moonshot Initiative (Digital Medicine Society)industry consortium membershipCancerIQ joined the CancerX Moonshot initiative, an innovative partnership led by the Digital Medicine Society to accelerate innovation in cancer care.
- Invitaeanchor member of canceriq lab networkAnchor member of the CancerIQ Lab Network (launched November 2020). Invitae is listed within CancerIQ's platform at the point of care, and CancerIQ prepopulates test requisitions and insurance prior-authorization forms with data from the encounter.
- Myriad Geneticsanchor member of canceriq lab networkAnchor member of the CancerIQ Lab Network (launched November 2020). Listed in CancerIQ's platform for streamlined genetic test ordering at the point of care.
- Eurofins EGL Genetic Diagnosticsanchor member of canceriq lab networkAnchor member of the CancerIQ Lab Network (launched November 2020). Listed in CancerIQ's platform for streamlined genetic test ordering.
- Eurofins NTDanchor member of canceriq lab networkAnchor member of the CancerIQ Lab Network (launched November 2020). Listed in CancerIQ's platform for streamlined genetic test ordering.
- LabCorpanchor member of canceriq lab networkAnchor member of the CancerIQ Lab Network (launched November 2020). Listed in CancerIQ's platform for streamlined genetic test ordering.
- GeneMattersflagship telehealth partnerCombined telehealth genetic counseling solutions with CancerIQ's cancer risk assessment platform to bring genetic expertise directly to patients regardless of location.
- Epic Systems (Epic App Orchard)flagship ehr integration partnerCancerIQ is integrated with Epic's App Orchard and works as a smart application within the Epic workflow — OSF HealthCare uses CancerIQ "all within Epic's workflow," and Adventist Health has integrated CancerIQ with Cerner.
- Cerner (Oracle Health) — Cerner App Galleryflagship ehr integration partnerAdventist Health integrated CancerIQ with Cerner in 2019; CancerIQ is listed in the Cerner App Gallery for embedded deployment.
- University of Chicago (Dr. Olopade, Dr. Guindalini, Dr. Obeid)founding research partnerEarly academic partner since CancerIQ's founding in 2014; co-developed genetics workflow solutions with Dr. Olufunmilayo (Funmi) Olopade, who is also CancerIQ's co-founder and Chief Scientific Officer.
- City of Hope (Kathy Blazer, Dr. Weitzel)early strategic partnerEarly partner since CancerIQ's founding era; co-developed the original genetic counseling and testing workflow for high-risk patient populations; hosts the annual Clinical Cancer Genetics & Genomics Conference at which CancerIQ presents.
- McKesson (referenced)minor industry referenceMcKesson published a release referencing CancerIQ's $14 million Series B funding round, indicating industry-aligned distribution/PR overlap.
Scale indicators20 records
Recent moves6 records
Expansion highlights6 records
CancerIQ competitors and assessment
Company assessmentDirect peers
- Syapse: Syapse is a precision medicine platform for oncology that helps health systems use real-world evidence and molecular data to inform cancer treatment decisions. Directly comparable to CancerIQ as enterprise health-system software turning molecular/clinical data into actionable oncology pathways.
- 2bPrecise: 2bPrecise is a precision medicine decision-support platform that integrates genomic and clinical data into the EHR workflow for oncologists and genetics providers. Direct competitor to CancerIQ, sharing the same EHR-embedded precision-oncology CDS model and target buyer (oncology and genetics programs).
- N-of-One (Qiagen Clinical Insights): N-of-One, now part of Qiagen Clinical Insights, provides molecular tumor board interpretation and clinical decision support for oncologists. Direct comparable to CancerIQ's molecular interpretation and clinical pathway generation capabilities, serving similar oncology and pathology customers.
Broad incumbents
- Flatiron Health: Flatiron Health (Roche subsidiary) is a leading oncology-specific EHR, real-world data, and clinical trials platform. Comparable to CancerIQ as a deeply embedded oncology data and decision support company, but at much larger scale and broader scope across community oncology and life sciences R&D.
- Tempus: Tempus combines molecular profiling, real-world data, and AI-driven clinical decision support in oncology. Comparable to CancerIQ in providing AI-enabled oncology intelligence to clinicians, but Tempus also operates its own diagnostic lab, giving it a vertically integrated model rather than a software-only platform.
- Foundation Medicine: Foundation Medicine (Roche subsidiary) provides comprehensive genomic profiling and a molecular insights platform used by oncologists. Comparable to CancerIQ on the molecular interpretation side, but Foundation is a diagnostic lab first with a software layer, while CancerIQ is software-first with a lab network partner ecosystem.
- Philips Oncology Informatics: Philips offers oncology informatics solutions including clinical decision support, tumor board workflows, and population health analytics within its broader health technology portfolio. Broad incumbent with overlapping CDS and oncology pathway capabilities, though not focused specifically on hereditary cancer and genetic risk assessment.
- Caris Life Sciences: Caris is a molecular profiling and precision oncology company that combines comprehensive tumor profiling with an AI-driven molecular profiling platform (MI Profile, MI Cancer Seek) and an oncology decision support network. Comparable to CancerIQ at the intersection of cancer genomics and clinical intelligence, but vertically integrated with its own lab.
Emerging players
- Perthera: Perthera is a precision oncology decision-support company that combines multi-omic profiling with AI-driven treatment recommendations and molecular tumor board services. Emerging player with overlap in cancer risk assessment and clinical pathway tools for community oncology.
Regional players
- Navican (Intermountain Healthcare): Navican is the precision cancer care subsidiary of Intermountain Healthcare, offering precision oncology decision support and tumor board services. Comparable to CancerIQ as an oncology precision-medicine platform, but primarily serves Intermountain-affiliated and regional US health systems rather than the nationwide footprint CancerIQ has built.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
CancerIQ social profiles
Digital presenceCancerIQ compliance and trust
Trust signalCompliance3 records
CancerIQ financial estimates
Financial estimateRevenue estimate
Valuation estimate
CancerIQ leadership team
Management profileNumber of profiles
Profiles8 records
CancerIQ funding detail
Funding detailFunding overview
Funding rounds8 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CancerIQ M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CancerIQ
What does CancerIQ do?
CancerIQ is a cloud-based precision health intelligence platform that health systems use to identify patients at hereditary cancer risk, run genetic risk assessments at the point of care, and navigate high-risk patients into appropriate genetic testing, screening and preventive care. The platform combines risk-stratification algorithms, automated pedigree and documentation generation, a multi-lab test ordering marketplace, EHR-native workflows, longitudinal care management and analytics. It is sold primarily as an enterprise SaaS subscription with professional services, and is deployed across 200+ clinical locations in the United States.
Is CancerIQ a public or private company?
CancerIQ is a private company. It is classified as venture growth investor backed and is currently operating.
When was CancerIQ founded?
CancerIQ was founded in 2013. It employs 11 to 50 people.
Where is CancerIQ based?
CancerIQ is headquartered in Chicago, United States, in the North America region.
How does CancerIQ make money?
Three revenue lines are on record. Enterprise SaaS Subscription (Software & Services) is the primary driver. The others are professional Services / Customer Success and virtual Care / Genetic Counseling Services.
Who are CancerIQ's main competitors?
Direct peers on record are Syapse, 2bPrecise and N-of-One (Qiagen Clinical Insights). Broad incumbents are Flatiron Health, Tempus, Foundation Medicine, Philips Oncology Informatics and Caris Life Sciences. Perthera is listed as an emerging player. Navican (Intermountain Healthcare) is listed as a regional player.
Does CancerIQ have an API?
Yes. CancerIQ exposes an API at api.canceriq.com that is accessed via the OAuth2 protocol (brokered through Auth0) during user authentication. No public documentation, SDKs, sample code, rate limits, or feature description were provided in the source material.
What industry is CancerIQ in?
CancerIQ's product category is Precision Health / Hereditary Cancer Risk Software. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLALAGAH, Oncology Telemedicine Platforms. Its NAICS code is 51321 and its SIC code is 7372.